Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04028687 · ClinicalTrials.gov registry record

MDR - PMCF Study for Taperloc Complete Stems

A clinical trial of Hip Fractures and Hip Injuries, sponsored by Zimmer Biomet.

Recruiting
Registry status
820
Enrollment target
3
Study locations

NCT04028687 is a study of Hip Fractures and Hip Injuries that is actively recruiting participants, run by Zimmer Biomet. The registered enrollment target is 820 participants, above the 567-participant average among 15 other Hip Fractures trials with a reported enrollment target (45% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04028687, a study of Hip Fractures and Hip Injuries, is actively recruiting participants, sponsored by Zimmer Biomet.

RECRUITING
Registry status
820 participants
Enrollment target
3
Study locations

Study Summary

The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up\*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.

Interventions

  • DEVICE Taperloc Complete Stem

Study Locations (3)

Nevada

  • Orthopaedic Institute of Henderson - Henderson

Texas

  • Texas Health Physicians Group - Plano

Washington

  • Proliance Orthopaedics and Sports Medicine - Bellevue

Trial Details

FieldValue
Enrollment Target 820 participants
Start Date 2020-02-13
Est. Completion 2032-02-12

Sponsor

Zimmer Biomet

115 total trials

What the Registry Record Tells You About NCT04028687

The ClinicalTrials.gov registry entry for NCT04028687 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 820 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 567-participant average among 15 other Hip Fractures trials with a reported enrollment target (45% higher). The listed sponsor is Zimmer Biomet, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Hip Fractures appearing as the primary indexed condition, and to 1 intervention - of which Taperloc Complete Stem is the first listed.

NCT04028687 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Nevada, Texas, Washington.

Frequently Asked Questions

What is clinical trial NCT04028687 about?

NCT04028687 is a clinical study titled "MDR - PMCF Study for Taperloc Complete Stems". The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up\*. Since Taperloc Complete was introduced t...

What is the current status of trial NCT04028687?

This trial is currently recruiting. The enrollment target is 820 participants. The study started on 2020-02-13. Estimated completion is 2032-02-12.

What conditions does trial NCT04028687 study?

This clinical trial studies the following conditions: Hip Fractures, Hip Injuries, Hip Arthritis, Hip Pain Chronic, Hip Disease.

What interventions are being tested in trial NCT04028687?

The interventions under investigation include: Taperloc Complete Stem (DEVICE).

Who is sponsoring clinical trial NCT04028687?

This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04028687 being conducted?

This trial has 3 study locations across Nevada, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hip Fractures

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.